ACE and COVID-19: The use of ACEIs (angiotensin-converting enzyme inhibitors) and ARBs (angiotensin II receptor blockers) have been shown in animal models to increase ACE2 expression6,7, thus leading to controversy over its continued use in patients with COVID-19.